Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib with or without Camrelizumab in advanced intrahepatic cholangiocarcinoma after ≥2 prior systemic therapies
ChiCTR2600124310Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dalpiciclib and camrelizumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Disease control rate (DCR) and Objective response rate (ORR). Planned start May 2026; status: not yet recruiting.
02
Drugs
dalpiciclibcamrelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2600124310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124310.